FDA Approves Therapy to Treat Patients with Relapsed and Refractory Mantle Cell Lymphoma Supported by Clinical Trial Results Showing High Response Rate of Tumor Shrinkage

Press release from the U.S. Food and Drug Administration (FDA) curated by Editor in Chief George Lundberg, MD, who notes: 

Of the non-Hodgkin lymphomas, mantle cell lymphoma can be especially difficult to treat. The FDA has now announced accelerated approval for the drug zanubrutinib (Brukinsa) after it showed strong effects for patient in single-arm clinical trials.

Go to full article published by the U.S. Food and Drug Administration (FDA).

If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.